Regarding the management of cervical intraepithelial neoplasia (CIN), all of the following statements are true EXCEPT:

Explanation

## Analysis of CIN Management Principles ### Correct Statements (Options A, C, D) **Option A — HPV Testing at 12 Months Post-Treatment** **High-Yield:** Per ASCCP 2019/2020 guidelines, co-testing (cytology + HPV testing) or HPV testing alone at 12 months post-treatment is a recommended and accepted method to assess treatment efficacy in women treated for CIN 2/3. HPV testing at 12 months is increasingly used as the primary surveillance tool because persistent high-risk HPV positivity is a strong predictor of residual or recurrent disease. This statement is TRUE. **Option C — LEEP as Diagnostic and Therapeutic** **Clinical Pearl:** Loop electrosurgical excision procedure (LEEP) is both diagnostic and therapeutic. It: - Removes the transformation zone and lesion completely - Provides a specimen for histopathological examination - Allows assessment of ectocervical and endocervical margin status - Can be performed in an outpatient setting under local anesthesia This statement is TRUE. **Option D — CIN 1 Regression in Young Women** **Key Point:** CIN 1 has spontaneous regression rates of 60–90% in women aged <25 years. Current guidelines (ASCCP 2019) strongly recommend observation with repeat cytology or HPV testing rather than immediate excisional treatment in this age group, as the risk of progression is very low and treatment carries risks to future pregnancies. This statement is TRUE. ### Incorrect Statement (Option B) — Cold Knife Conization as Gold Standard for CIN 3 **Warning:** This is the EXCEPT answer. The claim that cold knife conization (CKC) is the **gold standard** for management of CIN 3 is **not accurate** by current standards. | Feature | LEEP | Cold Knife Conization | | --- | --- | --- | | **Efficacy for CIN 3** | Equivalent | Equivalent | | **Margin assessment** | Good (minor thermal artifact) | Excellent (no thermal artifact) | | **Morbidity** | Lower | Higher (requires GA/spinal) | | **Current preference** | First-line for CIN 2/3 | Reserved for specific indications | | **Setting** | Outpatient/office | Operating theatre | **Key Point:** LEEP is the **preferred first-line excisional treatment** for CIN 2/3 due to equivalent cure rates, lower morbidity, outpatient feasibility, and cost-effectiveness. CKC is reserved for specific situations such as suspected microinvasive disease, unsatisfactory colposcopy, or when LEEP margins are inadequate. Calling CKC the "gold standard" for CIN 3 management is outdated and not supported by current ASCCP or FIGO guidelines. While CKC does provide superior margin assessment due to absence of thermal artifact, this advantage does not make it the gold standard for routine CIN 3 management. **[cite: ASCCP 2019 Guidelines; Williams Gynecology 4e Ch 29; Berek & Novak's Gynecology 16e]** ### Summary Table: CIN Management by Grade | CIN Grade | Age <25 | Age ≥25 | Preferred Treatment | | --- | --- | --- | --- | | **CIN 1** | Observation | Observation or LEEP | Observation preferred | | **CIN 2** | Observation (age-specific) | LEEP | LEEP first-line | | **CIN 3** | LEEP or CKC | LEEP (preferred) | LEEP first-line; CKC for specific indications |